Taking stock of the drug industry, from the lab to the medicine chestJuly 24, 2023Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer Adobe STAT+ | Roche's $3 billion Alnylam deal shows drug firms are interested in long-acting heart drugs As part of the deal, Roche will pay $310 million for rights to a hypertension treatment, zilebesiran, invented by the biotech firm Alnylam. By Matthew Herper STAT+ | Lobbying spending dropped for companies that departed PhRMA Three companies that recently left PhRMA, AbbVie, Teva, and AstraZeneca, all spent less on lobbying after their departures. By Rachel Cohrs STAT+ | A new lobby shop looks to remind Congress about NIH's translational research arm NIH's translational research arm is getting a new lobbyist to make sure Congress doesn't forget about it, as focus shifts to ARPA-H. By Sarah Owermohle Adobe Opinion: Drug pricing and the 'impossible trinity' for patients Patients want three things from insurers: access to new drugs, low out-of-pocket costs, and low drug prices. They can't get them all. By Keith Ericson and Tal Gross STAT+ | Lawsuit says Cigna illegally denies claims in bulk, sticking patients with unexpected bills A new lawsuit accuses Cigna of using an algorithm to automatically deny claims in bulk instead of individually reviewing each case. By Tara Bannow More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments